Keywords: Boehringer Ingelheim, Volasertib, Ph III, Acute myeloid leukemia, AML
Boehringer Ingelheim starts pivotal trial of volasertib in AML
Article | 01 March 2013
German family-owned drug major Boehringer Ingelheim has started a Phase III trial of its polo-like kinase (Plk) inhibitor volasertib alongside ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
